Treatment failure gout: Failure to treat?

Rheumatology

Volumn 49, Issue 12, 2010, Pages 2233-2234

  Perry, Martin E ^a   Madhok, Rajan ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CREATININE; HLA B ANTIGEN; HLA B27 ANTIGEN; MERCAPTOPURINE; THIAZIDE DIURETIC AGENT; URIC ACID;

AGE; CLINICAL DECISION MAKING; CLINICAL EVALUATION; COMORBIDITY; CREATININE CLEARANCE; DRESS SYNDROME; DRUG DOSE ESCALATION; DRUG TREATMENT FAILURE; EDITORIAL; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; GOOD CLINICAL PRACTICE; GOUT; HAPLOTYPE; HUMAN; KIDNEY FAILURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RASH; RISK FACTOR; TREATMENT PLANNING; URIC ACID BLOOD LEVEL;

ALLOPURINOL; DRUG HYPERSENSITIVITY; GENERAL PRACTICE; GOUT; GOUT SUPPRESSANTS; GUIDELINE ADHERENCE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE; URIC ACID;

EID: 78549232674     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq143     Document Type: Editorial

References (16)

1. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary care population with the EULAR gout recommendations. Ann Rheum Dis 2006;66:1311-5.
2. Kleinman NL, Brook RA, Patel PA et al. The impact of gout on work absence and productivity. Value in Health 2007; 10:231-7.
3. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006;58: 87-114.
4. Riedel AA, Nelson M, Ridge NJ, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrolees with gout. J Rheum 2004;31: 1575-82.
5. Kumar A, Edward N, White MI, Johnston PW, Catto GRD. Allopurinol, erythema multiforme and renal insufficiency. Br Med J 1996;312:173-4.
6. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitisation to allopurinol following cutaneous reactions. Arthritis Rheum 2001;44:231-8.
7. Rider TG, Jordan KM. The modern management of gout. Rheumatology 2010;49:5-14.
8. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3.
9. Hung S-L, Chung W-H, Liou L-B et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102:4134-9.
10. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76: 47-56.
11. Schlesinger N. Management of acute and chronic gouty arthritis. Drugs 2004;64:2399-416.
12. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312-24.
13. Jordan KM, Cameron JS, Snaith M et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46:1372-4.
14. Cabana MD, Rand CS, Powe NR et al. Why don't physicians follow clinical practice guidelines? JAMA 1999;282: 1458-65.
15. Freidson E. Profession of medicine. A study of the sociology of applied knowledge. New York, NY: Harper & Row, 1970:168-9.
16. Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis 2007;66:1269-70.